ABSTRACT
@#AIM:To explore the efficacy of Qingre Huayu Recipe in the treatment of non-proliferative diabetic retinopathy(NPDR).<p>METHODS:We selected 84 cases of 84 eyes of NPDR patients diagnosed as “heat-blocking type” in the Department of Ophthalmology of our hospital during June 2016 to December 2017. According to the random number table method, 42 cases were divided into control group and experimental group respectively. On the basis of conventional hypoglycemic treatment, the control group was treated with calcium hydroxy benzene sulfonate capsules, and the observation group was treated with Qingre Huayu Recipe for 6wk. The improvement of visual acuity, fundus lesions and clinical efficacy before and after treatment were observed.<p>RESULTS:Before treatment, there was no significant difference in visual acuity between the two groups(<i>P</i>>0.05). After 6wk of treatment, the visual acuity of the experimental group(0.21±0.11)was significantly better than that of the control group(0.30±0.13), and the difference was statistically significant(<i>P</i><0.05). After 6wk of treatment, the fundus improvement efficiency and clinical efficacy(78.6% and 71.4%)were higher in the experimental group than in the control group(45.2% and 40.5%). There were significant differences in the improvement of fundus and clinical efficacy between the two groups(<i>P</i><0.05).<p>CONCLUSION:On the basis of traditional hypoglycemic treatment, Qingre Huayu Recipe has good curative effect on NPDR(heat-blocking type), which can improve the prognosis of patients. It is in line with syndrome differentiation and treatment, and provides ideas for Chinese medicine treatment of NPDR.
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the method of constructing small-diameter vascular grafts from xenogenic decellularized arterial matrices and mesenchymal stem cells (MSCs).</p><p><b>METHODS</b>Porcine iliac arteries were decellularized by detergent and trypsin treatment. Histology, mechanical strength and porosity experiments were performed to evaluate the properties of decellularized matrices. MSCs were isolated from bone marrow of dogs and expanded ex vivo. Decellularized matrices were seeded with MSCs and further cultured in a pulsatile bioreactor. Morphological features of the tissue engineered grafts were assayed by HE staining and scanning electron microscopy.</p><p><b>RESULTS</b>After cell extraction, absence of cellular components and preservation of extracellular matrix were verified. Mechanical strength of decellularized matrices was slightly reduced compared with native arteries. Porosity of decellularized matrices was 94.9%. Decellularized matrices were successfully seeded with MSCs, which grew to a near-confluent monolayer under flow conditions and MSCs were highly elongated and oriented to the flow direction.</p><p><b>CONCLUSION</b>Small-diameter vascular grafts can be constructed by seeding MSCs onto xenogenic decellularized arterial matrices and culturing in a pulsatile bioreactor.</p>
Subject(s)
Animals , Arteries , Blood Vessel Prosthesis , Cells, Cultured , Extracellular Matrix , Mesenchymal Stem Cells , Tissue EngineeringABSTRACT
<p><b>OBJECTIVE</b>To investigate the management of complicated, severe or recurrent Budd-Chiari syndrome.</p><p><b>METHODS</b>From February 2004 to August 2007, 28 patients with complicated, severe or recurrent Budd-Chiari syndrome were treated. In this series, 16 patients relapsed after treated with percutaneous transluminal angioplasty or stent deployment, 2 cases relapsed after surgery; and the other 10 were under severe conditions and hard to treat, including malignancy of the inferior vena cava and right atrium. Meso-cavo-atrial shunt was carried out in 10 cases, meso-cavo-jugular shunt in 6 (capitis medusa was used in one case), cavoatrial shunt in 2 and cavo-jugular shunt in 1, mesocaval shunt in 2, and radical or extended radical correction in 7.</p><p><b>RESULTS</b>One patient (3.6%) died in 24 hours after operation. Graft infection occurred in 1 case. Excellent, good, fair, poor and death rate were 22.2%, 55.5%, 14.8%, 3.7% and 3.7%, respectively, the overall effective rate was 92.5%.</p><p><b>CONCLUSION</b>To select personalized treatment according to the disease status brings hopes to difficult, severe, recurrent Budd-Chiari syndrome.</p>